52938-94-0

Usage

Uses

Used in Pharmaceutical Industry:
5-(4-Cyanophenyl)-furane-2-carboxylic acid is used as a reagent for the preparation of dihydrooxadiazole series of non-ATP-competitive MK2 inhibitors. These inhibitors are being developed as potential treatments for inflammatory diseases such as arthritis. 5-(4-Cyanophenyl)-furane-2-carboxylic acid plays a crucial role in the synthesis of these inhibitors, which target the MK2 enzyme, a key player in the inflammatory response.

Upstream product

• 88-14-2 2-furanoic acid 
• 873-74-5 4-Aminobenzonitrile 
• 126747-14-6 4-cyanophenylboronic acid 
• 834884-75-2 5-(4-cyanophenyl)furan-2-carboxylic acid methyl ester 
• 2527-99-3 methyl 5-bromo-2-furoate 
• 585-70-6 5-bromo-furan-2-carboxylic acid 

Downstream Products

• 299203-59-1 ethyl 5-(4-cyanophenyl)-2-furancarboxylate 
• 779316-86-8 5-(4-amidinophenyl)-2-furancarboxylic acid 
• 299203-61-5 5-[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]-2-furancarboxylic acid 
• 299203-64-8 5-[4-[(N-isopropyl)amidino]phenyl]-2-furancarboxylic acid 
• 752975-69-2 5-[4-[(N-cyclopropyl)amidino]phenyl]-2-furancarboxylic acid 
• 1007197-71-8 C₁₉H₁₄N₂O₂ 
• 1355617-72-9 C₂₇H₂₈N₄O₄ 
• 1355617-73-0 C₃₄H₃₃BrN₄O₄ 
• 1353884-84-0 C₂₉H₃₂N₄O₅ 
• 1353884-85-1 C₂₉H₃₃N₅O₅ 
• 1353884-47-5 4-(5-(4-(4-(piperazin-1-yl)phenyl)-5,6-dihydro-4H-1,2,4-oxadiazin-3-yl)furan-2-yl)benzonitrile 
• 597565-49-6 5-(4'-carboxyphenyl)-2-furanylcarboxylic acid 

Relevant academic research and scientific papers

Synthesis and SAR of 5-aryl-furan-2-carboxamide derivatives as potent urotensin-II receptor antagonists

The synthesis and biological evaluation as potential urotensin-II receptor antagonists of a series of 5-arylfuran-2-carboxamide derivatives 1, bearing a 4-(3-chloro-4-(piperidin-4-yloxy)benzyl)piperazin-1-yl group, are described. The results of a systemat

Discovery and development of novel salicylate synthase (MbtI) furanic inhibitors as antitubercular agents

We report on the virtual screening, synthesis, and biological evaluation of new furan derivatives targeting Mycobacterium tuberculosis salicylate synthase (MbtI). A receptor-based virtual screening procedure was applied to screen the Enamine database, identifying two compounds, I and III, endowed with a good enzyme inhibitory activity. Considering the most active compound I as starting point for the development of novel MbtI inhibitors, we obtained new derivatives based on the furan scaffold. Among the SAR performed on this class, compound 1a emerged as the most potent MbtI inhibitor reported to date (Ki = 5.3 μM). Moreover, compound 1a showed a promising antimycobacterial activity (MIC99 = 156 μM), which is conceivably related to mycobactin biosynthesis inhibition.

Hedgehog signal pathway inhibitor

The invention provides a Hedgehog signal pathway inhibitor as well as stereoisomers, tautomers, hydrates, solvates or pharmaceutically acceptable salts thereof, and the structural formula of the inhibitor is as shown in a formula (I). The invention further provides a preparation method and application of a compound. The compound provided by the invention is novel in structure; a signal transduction pathway adjusted by Hedgehog protein, Ptch, Gli and/or Smo can be adjusted through the compound of the formula I.

Discovery and biological evaluation of 5-aryl-2-furfuramides, potent and selective blockers of the Nav1.8 sodium channel with efficacy in models of neuropathic and inflammatory pain

Nav1.8 (also known as PN3) is a tetrodotoxin-resistant (TTx-r) voltage-gated sodium channel (VGSC) that is highly expressed on small diameter sensory neurons and has been implicated in the pathophysiology of inflammatory and neuropathic pain. Recent studies using an NavL8 antisense oligonucleotide in an animal model of chronic pain indicated that selective blockade of Nav1.8 was analgesic and could provide effective analgesia with a reduction in the adverse events associated with nonselective VGSC blocking therapeutic agents. Herein, we describe the preparation and characterization of a series of 5-substituted 2-furfuramides, which are potent, voltage-dependent blockers (IC50 v1.8 channel. Selected derivatives, such as 7 and 27, also blocked TTx-r sodium currents in rat dorsal root ganglia (DRG) neurons with comparable potency and displayed > 100-fold selectivity versus human sodium (Na v1.2, Nav1.5, Nav1.7) and human ether-a-go-go (hERG) channels. Following systemic administration, compounds 7 and 27 dose-dependently reduced neuropathic and inflammatory pain in experimental rodent models.

Aromatic extended bisamidines: Synthesis, inhibition of topoisomerases, and anticancer cytotoxicity in vitro

A series of four aromatic extended bisamidines (12-15) differing in the nature of their terminal basic side chains were synthesized and evaluated for cytotoxic activity in MCF-7 cultured breast cancer cells. The concentrations of 12, 13, 14, and 15 needed to inhibit [3H]thymidine incorporation into DNA by 50% (IC50) were found to be 63 μM, 85 μM, 77 μM, and 97 μM, respectively. To test whether cytotoxic properties were related to DNA-binding and topoisomerase action, the bisamidines 12-15 were evaluated in a cell-free system. Data from the ethidium displacement assay showed that bisamidines 12-15 have significant affinity for DNA and show moderate specificity for AT base pairs. In the topoisomerase II assay, the relaxation of DNA was inhibited with all four drugs and the extent of inhibition was directly proportional to the drug concentration. This suggests that DNA binding may be implicated in the cytotoxicity of these bisamidines, possibly by inhibiting interactions between topoisomerase II and their DNA targets.